Cytokinetics CYTK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.36M+9.0% | $17.76M+817% | $1.94M-97.1% | $66.77M+4,129% | $1.58M-90.7% | ||
| $95.53M-8.5% | $104.4M+5.2% | $99.23M-11.8% | $112.55M+14.5% | $98.26M+4.9% | ||
| $104.9M— | —— | —— | —— | $57.37M— | ||
| —— | $91.72M+32.1% | $69.46M+5.7% | $65.72M+14.6% | $57.37M-8.0% | ||
| $3.38M+18.1% | $2.86M+6.8% | $2.68M+17.2% | $2.29M-0.7% | $2.3M-3.5% | ||
| $202.97M+3.5% | $196.12M+16.3% | $168.69M-5.4% | $178.28M+13.4% | $157.21M+0.8% | ||
| $202.97M+3.5% | $196.12M+16.3% | $168.69M-5.4% | $178.28M+13.4% | $157.21M+0.8% | ||
| -$183.62M-2.9% | -$178.37M-7.0% | -$166.76M-49.5% | -$111.51M+28.4% | -$155.63M-11.9% | ||
| -948.7%+55.9pp | -1,004.6%+7,609pp | -8,613.4%-8,446pp | -167%+9,689pp | -9,856.3%-9,035pp | ||
| $14.52M+1.7% | $14.27M+25.7% | $11.35M+2.4% | $11.08M+25.0% | $8.87M-0.8% | ||
| $11.02M-3.9% | $11.47M+11.9% | $10.25M-21.2% | $13M-5.1% | $13.7M-8.7% | ||
| -$206.03M-12.6% | -$183.03M+40.2% | -$306.18M-128% | -$134.37M+16.7% | -$161.38M-7.6% | ||
| -1,064.5%-33.6pp | -1,030.9%+14,784pp | -15,815%-15,614pp | -201.2%+10,019pp | -10,220.1%-9,334pp | ||
| -$1.67-11.3% | -$1.50+41.2% | -$2.55-128% | -$1.12+17.6% | -$1.36-7.9% | ||
| -$1.67-11.3% | -$1.50+41.2% | -$2.55-128% | -$1.12+17.6% | -$1.36-7.9% | ||
| 123.3M+2.6% | 120.1M+0.1% | 120M+0.4% | 119.5M+0.8% | 118.5M+5.8% | ||
| 123.3M+2.6% | 120.1M+0.1% | 120M+0.4% | 119.5M+0.8% | 118.5M+5.8% | ||
| $2.39M— | —— | —— | —— | $1.58M— | ||
| $160K— | —— | —— | —— | $0— | ||
| -$208.27M-14.2% | -$182.44M+40.4% | -$305.99M-125% | -$136.07M+16.1% | -$162.23M-6.0% | ||
| $1.5M+66.7% | $900K+28.6% | $700K-76.7% | $3M+850% | -$400K-133% | ||
| $1.52M— | —— | $6.6M— | —— | -$4.58M— | ||
| -$10.94M-169% | $15.96M+342% | -$6.6M-203% | $6.4M+144% | -$14.64M-189% | ||
| -$6.21M-124% | $26.37M+246% | $7.62M-45.5% | $13.99M+197% | -$14.37M-243% | ||
| -$2.06M-149% | $4.2M+167% | -$6.28M-235% | $4.64M+1,133% | $376K-95.5% | ||
| -$1.6M— | —— | -$2.8M+80.8% | -$14.6M-474% | $3.9M+185% | ||
| $7.77M-93.0% | $110.71M-66.5% | $330.47M+321% | $78.53M+1,552% | $4.75M+99.4% | ||
| -$145.46M-2.0% | -$142.65M-32.7% | -$107.51M+16.2% | -$128.24M+2.6% | -$131.62M-101% | ||
| $18.82M+17.2% | $16.06M+7.3% | $14.97M+13.6% | $13.18M-6.4% | $14.08M+3.1% | ||
| -$1.84M— | —— | $167K+120% | -$851K-57.3% | -$541K— | ||
| -$404K— | —— | $25K+103% | -$852K-173% | -$312K-192% | ||
| $106.52M-69.2% | $345.65M+3.0% | $335.45M+50.4% | $222.97M+40.1% | $159.11M+31.4% | ||
| $5.93M+5.1% | $5.64M-39.7% | $9.35M+126% | $4.15M-26.8% | $5.66M+339% | ||
| $19.36M+9.0% | $17.76M+817% | $1.94M-97.1% | $66.77M+4,129% | $1.58M-90.7% | ||
| $30.39M-0.4% | $30.51M-0.6% | $30.7M+11.5% | $27.54M+16.9% | $23.55M-10.3% | ||
| -$183.62M-2.9% | -$178.37M-7.0% | -$166.76M-49.5% | -$111.51M+28.4% | -$155.63M-11.9% | ||
| -$180.24M-2.7% | -$175.51M-7.0% | -$164.08M-50.2% | -$109.22M+28.8% | -$153.33M-12.2% | ||
| -$180.24M-2.7% | -$175.51M-7.0% | -$164.08M-50.2% | -$109.22M+28.8% | -$153.33M-12.2% | ||
| -931.2%+57.2pp | -988.5%+7,487pp | -8,475%-8,311pp | -163.6%+9,547pp | -9,710.6%-8,903pp | ||
| -$183.62M-2.9% | -$178.37M-7.0% | -$166.76M-49.5% | -$111.51M+28.4% | -$155.63M-11.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytokinetics's revenue?
- Cytokinetics (CYTK) generated $105.8M in revenue over the trailing twelve months, up 450.6% year over year.
- Is Cytokinetics profitable?
- Cytokinetics is not currently profitable: it reported a net loss of $829.6M over the trailing twelve months, a -784.0% net margin.
- What is Cytokinetics's earnings per share?
- Cytokinetics's diluted EPS over the trailing twelve months is $-6.84.
- Where does Cytokinetics's income statement data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
